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Brugada syndrome can be unmasked by several conditions including a febrile state, marked leukocytosis, and 
electrolyte disturbances. Herein, we describe a 62-year-old man with cholangiocarcinoma in the first reported case of 
Brugada syndrome onset following photodynamic therapy.
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INTRODUCTION
Brugada syndrome is typified by an electrocardio-
graphic (ECG) pattern of elevated ST-segments in the right 
precordial leads (V1–V3), a morphology similar to that 
seen in right bundle branch block, an absence of structural 
heart disease, and a high risk of ventricular fibrillation 
and sudden death [1]. Sodium channel blockers, fever, 
α-adrenergic agonists, β-adrenergic blockers, vagotonic 
agents, hyperkalemia, hypokalemia, hypercalcemia, aci-
dosis, tricyclic antidepressants, alcohol, and cocaine toxic-
ity all reportedly unmask the characteristic ST-segment 
elevation in right precordial leads [2,3]. In this article, 
we report a case of Brugada syndrome developing after 
photodynamic therapy (PDT) in a patient diagnosed with 
cholangiocarcinoma. 
CASE REPORT
A previously healthy 62-year-old man was admitted to 
the hospital for PDT following a diagnosis of cholangiocar-
cinoma (Klatskin tumor, type IV) made 1 month prior to 
admission. His only complaint upon admission was mild 
abdominal pain. An endoscopic retrograde biliary catheter 
for draining bile was already in place. The patient had a 
cigarette smoking history of 40 packs per year and was a 
heavy drinker. His vital signs were stable, and no signifi-
cant cardiopulmonary signs were evident. The electrocar-
diogram was normal (Fig. 1A). There was no prior family 
history of ventricular arrhythmias or sudden cardiac 
death. 
For scheduled PDT, the patient was injected intrave-
nously for over 5 minutes with a hematoporphyrin deriva-
tive-type photosensitizer (Photogem, 2 mg/kg; Photogem 
LLC. Co., Moscow, Russia). After 40 to 50 hours of PDT, 
light at a release power of 150 J/cm
2 was applied.
The patient was stable until 7 hours following the light 
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application, at which time he began to complain of feel-
ing febrile and having chills. His body temperature was 
38.4°C. Emergency laboratory tests revealed hepatic bio-
chemical abnormalities: an aspartate transaminase (AST) 
level of 247 U/L, alanine transaminase (ALT) of 140 U/L, 
and direct bilirubin of 0.8 mg/dL. 
One hour following the injection of antipyretics, the pa-
tient’s condition stabilized. His only complaint was general 
weakness, but he went into cardiac arrest 10 hours later. 
The ECG performed during the cardiopulmonary resusci-
tation revealed polymorphic ventricular tachycardia (Fig. 
1B). After electrical cardioversions (300 J × 3), the cardiac 
rhythm recovered to a sinus rhythm. The 12-lead ECG 
showed a right bundle branch block and a pronounced ST-
segment elevation in the precordial leads (V1, V2) consis-
tent with Brugada syndrome (Fig. 1C). Echocardiography 
revealed global left ventricular systolic dysfunction (ejec-
tion fraction 45%) with aneurysmal dilation of the mid to 
apical wall, suggestive of stress-induced cardiomyopathy. 
Recurrent ventricular tachyarrhythmia was absent. 
The 12-lead ECG was normal when assessed 2 days post-
attack (Fig. 1D), but the patient was comatose and showed 
irreversible hypoxic brain damage upon neurologic exami-
nation. One day following the attack, an intractable fever 
persisted despite antipyretics and antibiotics. Laboratory 
evaluation revealed increases in the white blood cell count 
(14,200/uL, 80% polynuclear neutrophils), C-reactive pro-
tein (19.9 mg/dL), and myocardial enzymes. The hepatic 
biochemistry deteriorated steadily with an AST level of 615 
U/L, ALT of 174 U/L, and total bilirubin of 8.5 mg/dL. The 
patient’s condition worsened with oliguria and azotemia. 
On the sixth day post-attack, the patient died of fulminant 
hepatic failure and sepsis due to obstruction of the biliary 
tract. Additional electrophysiologic examinations could 
not be performed.  
DISCUSSION
Several studies have demonstrated that fever unmasks 
the characteristic ECG pattern of Brudaga syndrome and 
precipitates ventricular arrhythmias [4]. Although one 
episode of fever had occurred prior to the attack in this 
patient, no fever arose during the ventricular arrhythmia. 
The fever was transient, returning 1 day post-attack, and 
then persisted, but the ECG had normalized, which is why 
the Brugada syndrome was not associated with a fever in 
this patient. 
PDT is an ablative treatment for rapidly proliferating 
tissues, including dysplastic and malignant lesions. It 
Figure 1. Development of Brugada syndrome following photodynamic therapy in a patient with cholangiocarcinoma. (A) Electrocardio-
gram upon admission. (B) Polymorphic ventricular tachycardia during arrest. (C) Brugada pattern electrocardiogram following cardio-
version. (D) Repeat electrocardiogram 2 days following ventricular tachycardia. 
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employs the administration of a photosensitizing drug 
followed by the application of a specific wavelength of 
light, leading to intracellular photoexcitation and injury. 
Three groups of photosensitizers are generally available, 
the most common of which comprises hematoporphyrin 
derivatives, which we used to treat this patient. The com-
plications and toxicities occurring from PDT for gastroin-
testinal disease are related to the associated endoscopic 
procedure, acute effects of the photosensitizing agent, the 
local inflammatory and scarring effects in the region of 
therapy, and systemic phototoxicity [5].
 Although some 
complications such as atrial fibrillation and congestive 
heart failure following PDT administration are reported 
rarely [6,7], the occurrence of ventricular arrhythmia 
such as Brugada syndrome post-PDT in cholangiocarci-
noma has not been documented. The exact mechanism 
by which PDT causes cardiac arrhythmia is incompletely 
understood, and because this patient was not febrile and 
lacked any abnormal laboratory findings except hepatic 
biochemical abnormalities before the PDT, we speculate 
that the PDT itself may have caused Brugada syndrome in 
this patient. 
In conclusion, we report the first case of Brugada syn-
drome following PDT administration in a patient with 
cholangiocarcinoma. When treating patients with PDT, 
physicians should be aware of the potential risk of ar-
rhythmic complications.
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